Consolidated Quarterly Performance:

Total income from operations increased by 18% to Rs 105.65 crore, which include other operating income (down by 98%) Rs 0.07 crore for the quarter ended December 2010. Its net sales increased by 24% to Rs 105.59 crore. At gross level, Revenues from specialty chemicals business (75% of gross sales) increased by 17% to Rs 78.94 crore, where as revenues pharma business (25% of gross sales) increased by 24% to 26.71 crore. Interestingly, it's operating margins expanded by 410 basis points on the back of decrease in consumption cost by 270 basis points as percentage to sales and net of stock adjustments. In addition, other expenses decreased by 200 basis points. Thus, operating profit increased by 44% to Rs 24.24 crore.

At PBIT level, margins from specialty chemical business expanded by 400 basis points to 20.6% resulting segment profit to increase by 45% to Rs 16.24 crore. Where as, margins from Pharma business expanded by 290 basis points to 24.2% resulting segment profit to increase by 41% to Rs 6.46 crore.

With increase in interest cost by 5% to Rs 6.02 crore and depreciation by 44% to Rs 1.54 crore, PBT was up by 65% to Rs 16.68 crore. With decrease in tax rate by 100 basis points to 20.2% facilitated the net profit to increase by 67% to Rs 13.31 crore.

Consolidated Nine Months Performance:

Consolidated net sales increased by 14% to Rs 296.25 crore for the nine months ended December 2010. Operating profit margins expanded by 260 basis points resulting operating profit to increase by 28% to Rs 63.29 crore. With decrease in interest cost by 15% to Rs 13.56 crore and increase in depreciation by 33% to Rs 5.58 crore, PBT was up by 50% to Rs 44.16 crore. With decrease in tax rate by whopping 510 basis points to 17% facilitated the net profit to increase by 60% to Rs 36.66 crore.

Other Information:

• The scrip closed on BSE at Rs 281.5, up by 5.64% on 31st January 2010